Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drug behemoth Pfizer
With that in mind, let's take a closer look at Pfizer's business and see what CAPS investors are saying about the stock right now.
|Founded (founded)||New York (1849)|
|Market Cap||$178.2 billion|
|Trailing-12-Month Revenue||$66.3 billion|
|Management||Chairman/CEO Ian Read
CFO Frank D'Amelio
|Return on Equity (average, past 3 years)||9.8%|
|Cash/Debt||$24.0 billion / $39.1 billion|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 90% of the 6,086 members who have rated Pfizer believe the stock will outperform the S&P 500 going forward.
[C]onsistently successful with a lot of options in the pipeline. Lipitor, Celebrex and of course, Viagra. When was the last time a commercial came on and we remembered other male medications, but mention Viagra, and everyone around knows what you're talking about. [Pfizer] is the consistent home run hit.
If you want market-beating returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its four-star rating, Pfizer may not be your top choice.
If that's the case, we've compiled a special free report for investors called "The 3 Dow Stocks Dividend Investors Need," which uncovers a few other juicy income opportunities. The report is 100% free, but it won't be around forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days.